Nadav Kidron compensation by year
ORAMED PHARMACEUTICALS Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $273,086 | $399,804 | $436,310 | $419,460 | $439,076 | $465,982 | $491,131 | $462,988 | $540,145 | $619,529 |
| Bonus | $195,729 | $123,000 | $148,795 | $224,975 | $220,582 | $300,000 | $275,150 | $242,576 | $270,767 | $379,935 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $1,995,666 | $4,847,380 | $904,920 | $1,224,760 | $3,709,269 |
| Option awards | $0 | $585,150 | $522,569 | $398,910 | $569,062 | $876,693 | $875,241 | $0 | $0 | $0 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $17,366 | $45,579 | $442,326 | $507,750 | $539,131 | $382,240 | $344,718 | $48,738 | $62,017 | $65,927 |
| Total | $486,181 | $1,153,533 | $1,550,000 | $1,551,095 | $1,767,851 | $4,020,581 | $6,833,620 | $1,659,222 | $2,097,689 | $4,774,460 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ORAMED PHARMACEUTICALS INC. DEF 14A filed August 3, 2026, accession 0001213900-26-084609, and prior-year filings.
How this page was built: the ORAMED PHARMACEUTICALS INC. filed document, accession 0001213900-26-084609. Every figure is read from that document and cited to the page and table it appears in. Filed August 3, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 26,750 | — | $13.89 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ORAMED PHARMACEUTICALS INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
ORAMED PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Nadav Kidron · this page | President, Chief Executive Officer and Chairman | $4,774,460 |
| Miriam Kidron | Chief Scientific Officer and director (5) | $2,166,384 |
| Joshua Hexter | Chief Operating and Business Officer | $1,882,398 |
Board service
ORAMED PHARMACEUTICALS board · FY2021–FY2025How this board is paid
Company policy: ORAMED PHARMACEUTICALS pays directors a $30,000 cash retainer and $10,000 in RSUs. As stated in ORAMED PHARMACEUTICALS's FY2025 proxy.
The full ORAMED PHARMACEUTICALS compensation record
free company briefThis page is one person within ORAMED PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ORAMED PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ORAMED PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ORAMED PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.